UJUrmila J. Joshi

Urmila J. Joshi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Urmila J. Joshi has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Heena R. Bhojwani

    Department of Pharmaceutical Chemistry Principal K. M. Kundnani College of Pharmacy, Colaba Cuffe Parade, Mumbai India

    5 shared publications
  • Akshada J. Joshi

    KM Kundanani College of Pharmacy

    4 shared publications
  • Ragini Sinha

    National Facility for High Field NMR, Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400 005, India

    4 shared publications
  • Girjesh Govil

    National Facility for High Field NMR, Tata Institute of Fundamental Research, Homi Bhabha Road, Mumbai 400 005, India

    3 shared publications
  • Akshada Joshi

    Principal K.M. Kundnani College of Pharmacy, Cuffe Parade, Mumbai 400 005, India

    2 shared publications
  • Divya M. Kanchan

    Department of Pharmaceutical Science and Technology, Institute of Chemical Technology, Mumbai, India

    2 shared publications

Latest Publications

  • Determining the Most Relevant Crystal Structure to Virtually Identify Type 1 Inhibitors of c-Met: Part A

    by Urmila Joshi, Khushboo Begwani

    C-Met is a receptor tyrosine kinase, which plays a crucial role in cell proliferation, migration and angiogenesis. Its dysregulation results in aberrant signalling, resulting in tumor growth and metastasis; an important target in cancer treatment. Multiple crystal structures from the protein data bank of c-Met bound to various inhibitors. Since the receptor tyrosine kinases are conformationally flexible receptors, each of these crystal structures represents a distinct conformation suited to accommodate the ligand. For the identification of new ligands as inhibitors of c-Met using computational methods, such a situation presents a challenge, as the use of some crystal structures for docking may result in the identification of false negatives. To address this issue, we have screened the available crystal structures of c-Met; bound to Type 1 inhibitors systematically to identify the most relevant crystal structure which can be used for docking. The procedure involved ascertaining the presence of Type 1 inhibitors in the crystal structure, self-docking to ensure the suitability of docking protocol, cross-docking to establish the ability of that crystal structure to accommodate chemically distinct ligands and followed by judging the ability of the top-ranked crystal structures to identify actives over decoys preferentially. The Enrichment Factors and other statistical parameters such as the number of outranking decoys, Robust Initial Enhancement, ROC, BEDROC and Diversity Enrichment Factor were also calculated and analysed. All the results pointed towards 3ZXZ outperforming in all the tests and thus can be used as the most appropriate crystal structure for virtual screening of Type 1 inhibitors of c-Met.

  • Synthesis and biological evaluation of benzamide‐chalcone hybrids as potential c‐Met kinase and COX‐2 inhibitors

    by Heena Bhojwani, Khushboo Begwani, Vikrant Bhor, Parul Bedi, Nafisa Balasinor, Sanketa Raut, Urmila Joshi

    C‐Met kinase and cyclooxygenase 2 (COX‐2) enzymes are two significant targets in tumor progression. Chalcone and benzamide moieties were combined using molecular hybridization to assess their potential as c‐Met kinase and COX‐2 inhibitors. 4‐Methylbenzamide and 4‐chlorobenzamide chalcone analogs were synthesized, characterized, and evaluated for antiproliferative activity on Michigan Cancer Foundation‐7 (MCF‐7), HT‐29, MDA‐MB‐231, COLO‐205, and A549 cell lines by sulforhodamine‐B stain (SRB) assay. Following the SRB assay, compounds were evaluated for their c‐Met kinase and COX‐2 inhibitory potential. All compounds inhibited COX‐2 with half‐maximal inhibitory concentration (IC50) 7h, 7i, 7j, 8f, and 8j inhibited c‐Met with IC50 7h was evaluated for its long‐term antiproliferative and anti‐migratory effects by colony formation and wound healing assay. It exerted these effects in a concentration‐dependent manner. Compounds 7j and 8j were further evaluated for in vitro antiangiogenic effects. Compound 7j exhibited moderate antiangiogenic effect while compound 8j exhibited strong effect. Compounds 7h, 7i, 7j, 8f, and 8j were evaluated for the serum protein binding, using the in vitro bovine serum albumin binding assay. The results indicated that the tested compounds bind to bovine serum albumin (BSA) and can be further explored by other studies.


  • Cinnamamide-chalcone derivatives as CDK2 inhibitors: synthesis, pharmacological evaluation, and molecular modelling study

    by Akshada J. Joshi, Heena R. Bhojwani, Urmila J. Joshi, Khushboo V. Begwani, Ojas S. Wagal, Sadhana S. Sathaye, Divya M. Kanchan


  • Homology Modelling, Docking-based Virtual Screening, ADME Properties, and Molecular Dynamics Simulation for Identification of Probable Type II Inhibitors of AXL Kinase

    by Heena R. Bhojwani, Urmila J. Joshi

    Background: AXL kinase is an important member of the TAM family for kinases which is involved in most cancers. Considering its role in different cancers due to its pro-tumorigenic effects and its involvement in the resistance, it has gained importance recently. Majority of research carried out is on Type I inhibitors and limited studies have been carried out for Type II inhibitors. Taking this into consideration, we have attempted to build Homology models to identify the Type II inhibitors for the AXL kinase. Methods: Homology Models for DFG-out C-helix-in/out state were developed using SWISS Model, PRIMO, and Prime. These models were validated by different methods and further evaluated for stability by molecular dynamics simulation using Desmond software. Selected models PED1-EB and PEDI1-EB were used for the docking-based virtual screening of four compound libraries using Glide software. The hits identified were subjected to interaction analysis and shortlisted compounds were subjected to Prime MM-GBSA studies for energy calculation. These compounds were also docked in the DFG-in state to check for binding and elimination of any compounds that may not be Type II inhibitors. The Prime energies were calculated for these complexes as well and some compounds were eliminated. ADMET studies were carried out using Qikprop. Some selected compounds were subjected to molecular dynamics simulation using Desmond for evaluating the stability of the complexes. Results: Out of 78 models inclusive of both DFG-out C-helix-in and DFG-out C-helix-out, 5 models were identified after different types of evaluation as well as validation studies. 1 model representing each type (PED1-EB and PEDI1-EB) was selected for the screening studies. The screening studies resulted in the identification of 29 compounds from the screen on PED1-EB and 10 compounds from the screen on PEDI1-EB. Hydrogen bonding interactions with Pro621, Met623, and Asp690 were observed for these compounds primarily. In some compounds, hydrogen bonding with Leu542, Glu544, Lys567, and Asn677 as well as pi-pi stacking interactions with either Phe622 or Phe691 were also seen. 4 compounds identified from PED1-EB screen were subjected to molecular dynamics simulation and their interactions were found to be consistent during the simulation. 2 compounds identified from PEDI1-EB screen were also subjected to the simulation studies, however, their interactions with Asp690 were not observed for a significant time and in both cases differed from the docked pose. Conclusion: Multiple models of DFG-out conformations of AXL kinase were built, validated and used for virtual screening. Different compounds were identified in the virtual screening, which may possibly act as Type II inhibitors for AXL kinase. Some more experimental studies can be done to validate these findings in future. This study will play a guiding role in the further development of the newer Type II inhibitors of the AXL kinase for the probable treatment of cancer.


  • Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies

    by Akshada Joshi, Heena Bhojwani, Ojas Wagal, Khushboo Begwani, Urmila Joshi, Sadhana Sathaye, Divya Kanchan

    Background: EGFR (Epidermal Growth Factor Receptor) and CDK2 (Cyclin Dependent Kinase 2) are important targets in the treatment of many solid tumors and different ligands of these receptors share many common structural features. Objective: The study involved the synthesis of benzamide-substituted chalcones and determination of their antiproliferative activity as well as a preliminary evaluation of EGFR and CDK2 inhibitory potential using both receptor binding and computational methods. Methods: We synthesized 13 benzamide-substituted chalcone derivatives and tested their antiproliferative activity against MCF-7, HT-29 and U373MG cell lines using Sulforhodamine B Assay. Four compounds were examined for activity against EGFR and CDK2 kinase. The compounds were docked into both EGFR and CDK2 using Glide software. The stability of the interactions for the most active compound was evaluated by Molecular Dynamics Simulation using Desmond software. Molecular docking studies on mutant EGFR (T790M, T790M/L858R, and T790M/C797S) were also carried out. Results: From the SRB assay, we concluded that compounds 1g, and 1k were effective in inhibiting the growth of the MCF-7 cell line whereas the other compounds were moderately active. Most compounds were either moderately active or inactive on U373 MG and HT-29 cell lines. Compounds 1g and 1k showed good inhibitory activity against CDK2 kinase while 1d and 1f were moderately active. Compounds 1d, 1f, 1g, and 1k were moderately active against EGFR kinase. Molecular docking reveals the involvement of one hydrogen bond with Met793 in binding with EGFR; however, it was not stable during the simulation and these compounds bind to the receptor mainly via hydrophobic contacts. This fact also points towards a different orientation of the inhibitor within the active site of EGFR kinase. Binding mode analysis for CDK2 inhibition studies indicates that hydrogen bonding interactions with Lys 33 and Leu83 are important for the activity. These interactions were found to be stable throughout the simulation. Considering the results for wild-type EGFR inhibition, the docking studies on mutants were performed and which indicate that the compounds bind to the mutant EGFR but the amino acid residues involved are similar to the wild-type EGFR, and therefore, the selectivity seems to be limited. Conclusion: These benzamide-substituted chalcone derivatives will be useful as lead molecules for the further development of newer inhibitors of EGFR and/or CDK2 kinases.


  • Open Access

    Cinnamamide-Chalcone Derivatives as CDK2 Inhibitors: Synthesis, Pharmacological Evaluation, and Molecular Modelling Study

    by Akshada J. Joshi, Heena R. Bhojwani, Urmila Joshi, Khushboo V. Begwani, Ojas S. Wagal, Sadhana S. Sathaye, Divya M. Kanchan

    A series of 13 novel cinnamamide-chalcone derivatives (2a-2m) were synthesized and evaluated for their antiproliferative activity against MCF-7, K562, U373MG, and HT-29 cell lines by SRB assay. Considering the activities on MCF-7 cell line, eight compounds were tested for the in-vitro CDK2 inhibition and four (2g, 2h, 2k and 2l) were found to possess good activity (IC5050 values. The most active compounds on CDK2 when docked in EGFR had lower docking scores. Only one compound interacts with Lys721 (β-3 region) and Met769 (hinge region). The stability of interactions with CDK2 was assessed for 2k and 2l by molecular dynamics simulation using Desmond software. In conclusion, three compounds possess excellent activity against MCF-7 cell line and good activity against CDK2.

  • SELECTION OF BEST CRYSTAL STRUCTURE FOR INITIATING DOCKING-BASED VIRTUAL SCREENING STUDIES OF CDK2 INHIBITORS: A CROSS-DOCKING AND DUD SET VALIDATION APPROACH

    by A. Joshi, H Bhojwani, U Joshi

    A total of 95 crystal structures of CDK2 were selected after considering criteria such as resolution and absence of missing residues in the active site; and subjected to cross-docking. 14 out of 95 crystal structures exhibited docking accuracy for greater than 70% of ligands at RMSD cut off 2Å in the cross- docking studies. These 14 crystal structures were selected for the second part of the study, which included validation using DUD sets and enrichment calculations. 8 out of 14 crystal structures possessed the enrichment factor of >10 at 1% of the ranked database. ROC-AUC, AUAC, RIE, and BEDROC were calculated for these 8 crystal structures. 2WXV produced maximum BEDROC (0.768, at α=8) and RIE (11.22). 2WXV as a single initial crystal structure in the virtual screening protocol is likely to produce more accurate results than any other single crystal structure.


  • SYNTHESIS AND ANTIPROLIFERATIVE ACTIVITY OF FLAVONOID DERIVATIVES: EFFECT OF B-RING SUBSTITUTION

    by U Joshi, A Anantram, A Joshi, K Gokhale, S. Shukla, R Sinha, S Srivastava, G. Govil

    Flavones, flavonols, flavanones and isoflavones constitute four important categories of naturally occurring flavonoids. These compounds possess good antiproliferative activity and can act as adjuvants to existing anticancer therapy. We have synthesized twenty synthetic flavonoids including flavones, flavonols, flavanones and isoflavones using Claisen-Schmidt condensation, Baker-Venkataraman rearrangement and related reactions. The synthesized compounds were evaluated for antiproliferative activity against MCF-7, K562 and HepG2 cell lines. Flavanones showed good activity against HepG2 cell lines whereas some flavones and isoflavones were active in inhibiting the growth of K562 and MCF-7 cell lines. The study underlines the importance of electron rich substituents on the B-ring of synthetic flavonoids.